Release issued 5th October 2002

The study, overseen by Prof. Derek Willoughby and completed by Dr. Chandan A.S. Alam, of the Department of Experimental Pathology of the William Harvey Institute at St. Bartholomew's and the Royal London School of Medicine and Dentistry, measured the ability of the TDS technology to deliver Hydroxyzine across the skin in a sufficient dose to accomplish a therapeutic outcome without a patch or other appliance. Data from the study confirms company claims that the TDS technology enables rapid penetration and increased blood concentrations of Hydroxyzine. This trial documents the seventh drug delivered successfully utilizing the TDS technology.

The model for the study was the white rat. Blood samples were obtained at the zero time point pre-dosing, thirty minutes, two hours and four hours. The formulation was successful at delivering a dose of the drug at a therapeutic level at the first two timepoints and sustained high levels over four hours. Concentrations at 30 minutes averaged 9.4 ng/mL. At two hours the average was 10.86 ng/mL and at four hours the average was 74.12 ng/mL. These results were deemed exciting by Dr. Alam and the faculty at the Harvey Institute and are certainly indicative of further development.

The need for alternative dosing capability as provided by transdermal means is particularly felt in the case of antihistamines where small variations in dose titrations can dramatically impact product safety and acceptance. Many patients of smaler body size can receive a too-large dose with standard tablet or capsule dosing. The TDS can effectively mitigate all of these issues with anti-histamines. The TDS accomplishes the therapeutic outcome that the drug is designed for with much smaller doses than oral equivalents as demonstrated in the company's successful pre-clinical studies of other drugs. By bypassing the gut and first-pass circulation from the gut to the liver, GI distress and liver toxicity are eliminated or minimized.

TransDermal Technologies is actively seeking a licensing partner or partners interested in exploiting this technology.

The TDS(tm) is a platform system that is designed to be modified for each application and is believed to enable the rapid, safe and effective delivery of many medicaments across intact skin by means of its sprayed on or applicator applied lotions.

Company Contact: Libby Handel, Ph.D, Director of Development -l.handel@transdermaltechnologies.com / 800-282-5511 / 561-848-9100

(30th May 2009) NSAID DANGERS COULD BE REDUCED WITH TDS (R) DELIVERY

(15th May 2009) TDS® TESTOSTERONE WILL LIKELY NOT REQUIRE BLACK BOX WARNINGS FROM FDA

(25th April 2009) TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

(15th March 2009) TTI's LANGFORD RESEARCH PARTNERS WITH SCI

(5th January 2009) TTI'S LANGFORD RESEARCH INSTITUTE TO OCCUPY LAB SPACE